Latest News & Features
Biotechnology
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report. 27 October 2020
Americas
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry. 26 October 2020
Big Pharma
The English High Court has lifted a stay on Amgen’s lawsuit which accused Sanofi-Aventis and Regeneron of infringing a patent covering pharmaceuticals which treat elevated cholesterol levels. 23 October 2020
Big Pharma
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US. 22 October 2020
Americas
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating. 22 October 2020
Americas
US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug. 22 October 2020
article
In the past year, the interplay between Intellectual Property Law and Antitrust Law has been prevalent in many landmark cases globally. In this session, we will be analysing the latest developments and judgements, and how they will affect the implementation of Intellectual Property in the future. 22 October 2020
Americas
Abbott Laboratories has asked an Illinois court to halt a former employee from using its name and trademarks to sell COVID-19 diagnostic tests. 21 October 2020
Biotechnology
Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement. 20 October 2020
Big Pharma
The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine. 20 October 2020